The Metabolomics Services Market Size was valued at USD 2.62 Billion in 2023. The Global Metabolomics Services industry is projected to grow from USD 2.94 Billion in 2024 to USD 7.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.28% during the forecast period (2024 - 2032).
Metabolomics can be described as examining and analyzing biochemical processes relating to intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reproduce all metabolites involved in numerous reactions in an organism, counting secondary metabolites, signaling molecules, hormones, and metabolic intermediates. Its application in toxicology, environmental analysis, disease research, agriculture, biofuel development & nutrition is estimated to be a broad scope for developing the metabolomics services market size in the coming period.
COVID-19 Analysis
The cold chain and pharmaceutical industries were impelled to revolutionize throughout vaccine development, including the production of temperature-controlled packages that met the revised deep-frozen vaccine storage requirements and amplified demand for existing products. The industry soared to the challenge posed by COVID, working by employing unique ways to bolster the metabolomics services market share. The metabolome is exceptionally dynamic, and metabolism shifts often lead to clinical phenotype changes. The use of metabolomics is being leveraged to shape our understanding of COVID-19, which could play a vital role. The fruitful cases for biomarker study in pneumonia, sepsis, and comorbidities related to many COVID-19 infections indicate the possibility of metabolomics to bring about an adapted health care strategy for Covid-19, delivering safe and effective treatments to patients.
April 2024: A biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, Sino Biological, Inc., which offers biological research reagents and related technical contract research services, is happy to disclose the founding of a services partnership with Toronto, Canada-based Rapid Novor, Inc. As per the terms of this deal, Sino Biological will market Rapid Novor's exclusive de novo REmAb monoclonal antibody (mAb) sequencing service in arrangement with its custom mAb development and production services. Geographic regions disguised under this collaboration include Singapore, Malaysia, Vietnam, Japan, China, Thailand, Indonesia, Philippines, and South Korea. Based in Beijing, China, Sino Biological is a supplier of mammalian cell-based recombinant antibodies, proteins, and related contract research services. A significant portion of its custom contract research services is the outline, development, and assembly of custom monoclonal antibodies for both in vitro diagnostics and basic research applications. The blend of offering monoclonal antibody active site amino acid and nucleic acid sequence information alongside the corresponding purified, bioactive antibody to clients will produce valuable insight into antibody structure and function, allowing users to boost antibody engineering strategies, safeguard intellectual property, build new diagnostics platforms and improve drug discovery.
February 2024: A biomarker discovery organization offering conveyed services for multi-omics data generation and analysis, Sapient, has disclosed the launch of high data discovery proteomics services, allowing the measurement of thousands of proteins in blood and tissue in a wide range of biological pathways. This range further continues Sapient's capabilities for dynamic biomarker discovery with its state-of-the-art mass spectrometry-based platform, which also supports its discovery of metabolomics and lipidomics approaches.
Growing Prevalence Of Cancer
The surge in cancer cases globally in different body areas is predicted to motivate the metabolomics services market size in the upcoming period.
Technological Advancements In Instrumentation
The breakthroughs in the instruments used for metabolomics related studies is estimated to enhance the global market considerably in the forecast period.
Increasing Application Of Metabolomics
The use of metabolomics in various studies for diverse ailments is predicted to spur the growth of the Metabolomics Services Market.
Expansion In Developing Countries
The development of emerging economies is estimated to shape the Metabolomics Services Market considerably in the forecast period. With increased funding for businesses' research and growth, it is predicted to transform the countries' metabolomics market.
High Cost Of Instruments
The raised costs associated with using the metabolomics tools and services are estimated to stagnate the growth of the Metabolomics Services Market.
Government Policies And Regulations
The strict regulations related to healthcare-related businesses are estimated to create fresh expansion opportunities in the forecast period.
The mass spectrometry segment is estimated to have a majority share of the global market, with metabolomics bioinformatics services coming in second through the forecast period.
The biomedical & pharmaceutical segment accounted for the largest market share in 2021 and is estimated to control the upcoming period's Metabolomics Services Market share.
Americas Regional Market To Lead With Vast Expertise
The Americas regional market is expected to hold the market's principal share. This is due to the swelling patient population base that is suffering from cancer, and cardiovascular diseases are predicted to boost the Metabolomics Services Market growth in this region.
Presence Of Strong Contenders To Spur European Region
The European market holds the next major position in the metabolomics services market. Numerous companies in the region provide metabolomics services, which is predicted to drive the region's growth in the metabolomics services market.
APAC To Be Incentivized By Huge Patient Base
The Asia Pacific regional metabolomics market is estimated to be the fastest mounting region due to many patient populations suffering from chronic disease and collective demand for therapy.
The prolific companies in the Metabolomics Services Market are
Recent Developments
Jan 2021 OWL and BIOSFER, biotech players, have arrived at a strategic partnership to reinforce R&D in developing diagnostic methods and personalized medicine use metabolomics. The agreement permits both groups to identify prospects, produce detailed proposals, and find the most suitable backing to safeguard these projects' victory and make them advantageous for society and the biotechnology industry. OWL and BIOSFER have widespread knowledge of metabolomic technology for application in various areas, such as increasing new biomarkers to create diagnostic products or encourage advanced platforms for studies and clinical tests in the pharmaceutical industry.
Jan 2021 numares A.G., a leading metabolomics diagnostics company, and Bruker Corporation have decided to cooperate to bring novel diagnostics tests employing NMR to the laboratory market unmet medical requirements. The tests are created on the automated measurement of metabolites via artificial intelligence and a strong magnetic field. The platform is advertised under the numares brand AXINON. This partnership will support the current transition of AXINON platform from research into routine clinical use and makes it accessible to all patients as a reasonably priced, day-to-day diagnostic standard.
Aug 2020 Metabolon, Inc., the global leader in metabolomics, has entered into a multi-year association with Merck KGaA, Germany, a top science and technology company. Merck KGaA, Germany, runs its biopharmaceuticals business in the U.S. and Canada as EMD Serono. Metabolon will back clinical & translational research developments through therapeutic areas as an exploratory metabolomics associate. Through this partnership, Metabolon will achieve worldwide metabolomics and deliver top biological interpretation and examination of the results to shed light on biomarkers and biochemical pathways detected to progress both the rapidity and yield of Merck KGaA's drug development pipeline.
July 2020 ReviveMed has announced that they are pursuing an assessment analysis with Bristol Myers Squibb. This analysis will use ReviveMed's artificial intelligence (A.I.) platform to understand the mechanisms of resistance and response to immunotherapies in cancer patients. ReviveMed has built one of the most comprehensive databanks about metabolites and their relation with other molecules. Their exclusive A.I. algorithm utilizes this database to classify a large number of metabolites for individual patients quickly and at a low cost. ReviveMed's AI-driven platform interprets this large number of data to discover novel disease mechanisms and molecules for drug discovery purposes.
Biomedical and Pharmaceutical
Agriculture
Food
| Report Attribute/Metric | Details |
| Market Size 2032 | USD 7.41 Billion |
| CAGR | 12.28% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product and Service, Application, End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Agilent Technologies, Inc. (US), Waters (US), Bruker (US), TMIC (CANADA), Thermo Fisher Scientific (US), Biocrates Life Sciences AG (AUSTRIA), Creative Proteomics (US), Human Metabolome Technologies America Inc (JAPAN), Shimazdu Corporation (Japan), and Metabolon, INC (US) |
| Key Market Opportunities | Expansion In Developing Countries |
| Key Market Drivers | · Growing Prevalence Of Cancer· Technological Advancements In Instrumentation· Increasing Application Of Metabolomics |
Metabolomics Services Market Highlights:
Frequently Asked Questions (FAQ) :
The valuation of the global metabolomics services market is estimated to reach USD 7.41 BN. by 2032.
The global metabolomics services market is projected to grow at approximately 12.28% CAGR during the forecast period (2024-2032).
Agilent Technologies, Inc. (US), Waters (US), Bruker (US), Thermo Fisher Scientific (US), TMIC (Canada), Biocrates Life Sciences AG (Austria), Metabolon, INC (US), Creative Proteomics (US), and Human Metabolome Technologies America Inc (Japan), are some of the major players operating in the metabolomics services market.
North America holds the largest share in the global metabolomics services market, followed by Europe and the Asia Pacific, respectively.
High prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
